NCT04592835View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

December 13, 2020

Study Completion Date

June 30, 2021

Conditions
COVID-19 Patients
Interventions
DRUG

DWRX2003

"Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites"

Sponsors
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY